Selected research
Industry Research
Dry Eye Syndrome Drugs Industry Research Report 2026
Market perspective
The global Dry Eye Syndrome Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Dry Eye Syndrome Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Dry Eye Syndrome Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Dry Eye Syndrome Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Dry Eye Syndrome Drugs include Johnson & Johnson, Novartis, United Laboratories, Jianfeng Group, AbbVie, URSAPHARM, Thea pharmaceuticals, Sun Pharmaceutical and SIMILASAN, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Dry Eye Syndrome Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dry Eye Syndrome Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dry Eye Syndrome Drugs Market by Company
Johnson & Johnson
Novartis
United Laboratories
Jianfeng Group
AbbVie
URSAPHARM
Thea pharmaceuticals
Sun Pharmaceutical
SIMILASAN
Santen Pharma
Rohto
Prestige Consumer Healthcare
OmniVision Pharma
LION
Kenvue (VISINE)
Bausch & Lomb
Alcon
Akorn
Dry Eye Syndrome Drugs Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Other
Dry Eye Syndrome Drugs Segment by Application
Homecare
Hospitals
Clinics
Others
Dry Eye Syndrome Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Eye Syndrome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dry Eye Syndrome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Eye Syndrome Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dry Eye Syndrome Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Artificial Tears
- Anti-inflammatory Drugs
- Other
Applications
- Homecare
- Hospitals
- Clinics
- Others
Companies covered
- Johnson & Johnson
- Novartis
- United Laboratories
- Jianfeng Group
- AbbVie
- URSAPHARM
- Thea pharmaceuticals
- Sun Pharmaceutical
- SIMILASAN
- Santen Pharma
- Rohto
- Prestige Consumer Healthcare
- OmniVision Pharma
- LION
- Kenvue (VISINE)
- Bausch & Lomb
- Alcon
- Akorn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dry Eye Syndrome Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Artificial Tears
- 2.2.3 Anti-inflammatory Drugs
- 2.2.4 Other
- 2.3 Dry Eye Syndrome Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Homecare
- 2.3.3 Hospitals
- 2.3.4 Clinics
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Dry Eye Syndrome Drugs Breakdown Data by Type
- 3.1 Global Dry Eye Syndrome Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Type (2027-2032)
4 Dry Eye Syndrome Drugs Breakdown Data by Application
- 4.1 Global Dry Eye Syndrome Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Dry Eye Syndrome Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dry Eye Syndrome Drugs Market Perspective (2021-2032)
- 5.2 Global Dry Eye Syndrome Drugs Growth Trends by Region
- 5.2.1 Global Dry Eye Syndrome Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dry Eye Syndrome Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Dry Eye Syndrome Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Dry Eye Syndrome Drugs Market Dynamics
- 5.3.1 Dry Eye Syndrome Drugs Industry Trends
- 5.3.2 Dry Eye Syndrome Drugs Market Drivers
- 5.3.3 Dry Eye Syndrome Drugs Market Challenges
- 5.3.4 Dry Eye Syndrome Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dry Eye Syndrome Drugs Players by Revenue
- 6.1.1 Global Top Dry Eye Syndrome Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Dry Eye Syndrome Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Dry Eye Syndrome Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dry Eye Syndrome Drugs Head Office and Area Served
- 6.4 Global Dry Eye Syndrome Drugs Players, Product Type & Application
- 6.5 Global Dry Eye Syndrome Drugs Manufacturers Established Date
- 6.6 Global Dry Eye Syndrome Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dry Eye Syndrome Drugs Market Size (2021-2032)
- 7.2 North America Dry Eye Syndrome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dry Eye Syndrome Drugs Market Size by Country (2021-2026)
- 7.4 North America Dry Eye Syndrome Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dry Eye Syndrome Drugs Market Size (2021-2032)
- 8.2 Europe Dry Eye Syndrome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dry Eye Syndrome Drugs Market Size by Country (2021-2026)
- 8.4 Europe Dry Eye Syndrome Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dry Eye Syndrome Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Dry Eye Syndrome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dry Eye Syndrome Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dry Eye Syndrome Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dry Eye Syndrome Drugs Market Size (2021-2032)
- 10.2 South America Dry Eye Syndrome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dry Eye Syndrome Drugs Market Size by Country (2021-2026)
- 10.4 South America Dry Eye Syndrome Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dry Eye Syndrome Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Dry Eye Syndrome Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dry Eye Syndrome Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dry Eye Syndrome Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.1.4 Johnson & Johnson Dry Eye Syndrome Drugs Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.2.4 Novartis Dry Eye Syndrome Drugs Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 United Laboratories
- 12.3.1 United Laboratories Company Information
- 12.3.2 United Laboratories Business Overview
- 12.3.3 United Laboratories Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.3.4 United Laboratories Dry Eye Syndrome Drugs Product Portfolio
- 12.3.5 United Laboratories Recent Developments
- 12.4 Jianfeng Group
- 12.4.1 Jianfeng Group Company Information
- 12.4.2 Jianfeng Group Business Overview
- 12.4.3 Jianfeng Group Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.4.4 Jianfeng Group Dry Eye Syndrome Drugs Product Portfolio
- 12.4.5 Jianfeng Group Recent Developments
- 12.5 AbbVie
- 12.5.1 AbbVie Company Information
- 12.5.2 AbbVie Business Overview
- 12.5.3 AbbVie Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.5.4 AbbVie Dry Eye Syndrome Drugs Product Portfolio
- 12.5.5 AbbVie Recent Developments
- 12.6 URSAPHARM
- 12.6.1 URSAPHARM Company Information
- 12.6.2 URSAPHARM Business Overview
- 12.6.3 URSAPHARM Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.6.4 URSAPHARM Dry Eye Syndrome Drugs Product Portfolio
- 12.6.5 URSAPHARM Recent Developments
- 12.7 Thea pharmaceuticals
- 12.7.1 Thea pharmaceuticals Company Information
- 12.7.2 Thea pharmaceuticals Business Overview
- 12.7.3 Thea pharmaceuticals Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.7.4 Thea pharmaceuticals Dry Eye Syndrome Drugs Product Portfolio
- 12.7.5 Thea pharmaceuticals Recent Developments
- 12.8 Sun Pharmaceutical
- 12.8.1 Sun Pharmaceutical Company Information
- 12.8.2 Sun Pharmaceutical Business Overview
- 12.8.3 Sun Pharmaceutical Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.8.4 Sun Pharmaceutical Dry Eye Syndrome Drugs Product Portfolio
- 12.8.5 Sun Pharmaceutical Recent Developments
- 12.9 SIMILASAN
- 12.9.1 SIMILASAN Company Information
- 12.9.2 SIMILASAN Business Overview
- 12.9.3 SIMILASAN Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.9.4 SIMILASAN Dry Eye Syndrome Drugs Product Portfolio
- 12.9.5 SIMILASAN Recent Developments
- 12.10 Santen Pharma
- 12.10.1 Santen Pharma Company Information
- 12.10.2 Santen Pharma Business Overview
- 12.10.3 Santen Pharma Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.10.4 Santen Pharma Dry Eye Syndrome Drugs Product Portfolio
- 12.10.5 Santen Pharma Recent Developments
- 12.11 Rohto
- 12.11.1 Rohto Company Information
- 12.11.2 Rohto Business Overview
- 12.11.3 Rohto Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.11.4 Rohto Dry Eye Syndrome Drugs Product Portfolio
- 12.11.5 Rohto Recent Developments
- 12.12 Prestige Consumer Healthcare
- 12.12.1 Prestige Consumer Healthcare Company Information
- 12.12.2 Prestige Consumer Healthcare Business Overview
- 12.12.3 Prestige Consumer Healthcare Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.12.4 Prestige Consumer Healthcare Dry Eye Syndrome Drugs Product Portfolio
- 12.12.5 Prestige Consumer Healthcare Recent Developments
- 12.13 OmniVision Pharma
- 12.13.1 OmniVision Pharma Company Information
- 12.13.2 OmniVision Pharma Business Overview
- 12.13.3 OmniVision Pharma Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.13.4 OmniVision Pharma Dry Eye Syndrome Drugs Product Portfolio
- 12.13.5 OmniVision Pharma Recent Developments
- 12.14 LION
- 12.14.1 LION Company Information
- 12.14.2 LION Business Overview
- 12.14.3 LION Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.14.4 LION Dry Eye Syndrome Drugs Product Portfolio
- 12.14.5 LION Recent Developments
- 12.15 Kenvue (VISINE)
- 12.15.1 Kenvue (VISINE) Company Information
- 12.15.2 Kenvue (VISINE) Business Overview
- 12.15.3 Kenvue (VISINE) Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.15.4 Kenvue (VISINE) Dry Eye Syndrome Drugs Product Portfolio
- 12.15.5 Kenvue (VISINE) Recent Developments
- 12.16 Bausch & Lomb
- 12.16.1 Bausch & Lomb Company Information
- 12.16.2 Bausch & Lomb Business Overview
- 12.16.3 Bausch & Lomb Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.16.4 Bausch & Lomb Dry Eye Syndrome Drugs Product Portfolio
- 12.16.5 Bausch & Lomb Recent Developments
- 12.17 Alcon
- 12.17.1 Alcon Company Information
- 12.17.2 Alcon Business Overview
- 12.17.3 Alcon Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.17.4 Alcon Dry Eye Syndrome Drugs Product Portfolio
- 12.17.5 Alcon Recent Developments
- 12.18 Akorn
- 12.18.1 Akorn Company Information
- 12.18.2 Akorn Business Overview
- 12.18.3 Akorn Revenue in Dry Eye Syndrome Drugs Business (2021-2026)
- 12.18.4 Akorn Dry Eye Syndrome Drugs Product Portfolio
- 12.18.5 Akorn Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst